Anderson-Fabry Disease Clinical Trial
— MyFABT1Official title:
Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease (AFD): Impact of Treatment by Agalsidase Alpha (Replagal®)
| NCT number | NCT02956954 |
| Other study ID # | 2016/092/HP |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | March 25, 2017 |
| Est. completion date | March 2020 |
Anderson Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by a deficiency
of the enzyme alpha-galactosidase. AFD can involve various organs and lead to a series of
clinical abnormalities. Left ventricular hypertrophy in middle-aged men is one of its life
threatening complications. It was shown that pending the absence of myocardial replacement
fibrosis, substitution therapy could improve myocardial morphology and function as well as
exercise capacity. Today, there is no available marker of the efficacy of the treatment on
the heart morphology and function.
The T1 time (or longitudinal relaxation time) is one of the major components of the image
formation in Magnetic Resonance Imaging (along with T2 time and proton density). Several
techniques have been described to assess the myocardial T1-time.
One of them called MOLLI (Modified Look Locker Inversion Recovery), was made available in
research centres by the Siemens company. In a study published in 2013, Sado et al. showed in
a series of various conditions (hypertension, AFD, hypertrophic cardiomyopathy, AL
amyloidosis, aortic stenosis and healthy volunteers) that a septal T1 below a threshold of
940ms could discriminate AFD patients. No overlap was shown with other conditions in this
study. Our experience with T1 mapping supports that finding (even though our threshold could
be slightly different), and we could recently detect by MRI a number of AFD patients, some of
them with hypertrophy, some others without hypertrophy. The effect of Replagal® on the T1
relaxation time remains unknown.
The purpose of that study was to follow-up the heart morphology, function and myocardial T1
relaxation time in a population of treated/untreated patients.
| Status | Recruiting |
| Enrollment | 25 |
| Est. completion date | March 2020 |
| Est. primary completion date | March 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patient with proven Anderson Fabry Disease - Patient with no Agalsidase alpha (Replagal®) treatment or - Patient with Agalsidase alpha (Replagal®) treatment ongoing Exclusion Criteria: - Pace Maker / Implantable Cardiac Defibrillator - Claustrophobia - Ocular foreign body - Allergy to gadolinium chelates - Pregnancy ongoing - Age < 18 years l |
| Country | Name | City | State |
|---|---|---|---|
| France | Rouen University Hospital | Rouen |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Rouen |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Difference from baseline in Septal myocardial T1 relaxation time | Septal myocardial T1 relaxation time will be evaluated using MRI for treated and untreated patient | 24 months | |
| Secondary | Difference from baseline in Septal myocardial T1 relaxation time | Septal myocardial T1 relaxation time will be evaluated using MRI for treated and untreated patient | 6 months | |
| Secondary | Difference from baseline in Septal myocardial T1 relaxation time | Septal myocardial T1 relaxation time will be evaluated using MRI for treated and untreated patient | 12 months | |
| Secondary | Difference from baseline in Septal myocardial T1 relaxation time | Septal myocardial T1 relaxation time will be evaluated using MRI for treated and untreated patient | 18 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01268241 -
The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease
|